Posts Tagged ‘world’
Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics – PR Newswire
Leadership change simultaneous to the Eclipse Cell Engineering platform spinout asEditCo Bio
REDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately. Craig Christianson has been appointed Chief Executive Officer following an extensive search process. Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor. Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enablingSynthego's unique focus on therapeutic applications of CRISPR.
"Founding and growing Synthego the past 12 years has been the privilege of a lifetime," said Dabrowski. "Our team has transformed the CRISPR landscape by staying true to our values and providing everyone, from individual scientists to the world's leading biotechnology companies, with unprecedented access to advanced genome engineering. I'm confident Craig is an ideal fit to further our mission by building a robust commercial engine leveraging Synthego's platform - in addition to his impeccable track record, he embodies Synthego's culture of innovation and excellence. As the world enters the era of CRISPR based therapeutics, Synthego is now focused to be the premier supplier to hundreds of programs entering the clinic."
Christianson has a track record of spearheading global commercial strategies, business development and operations to build global life sciences and other businesses. He joins Synthego from Water Street Healthcare Partners, preceded by 12 years with global biotechnology company Promega Corporation where he led commercial operations, accelerating their growth to $700M+ in annual sales through profit-driven strategies and successful digital transformation.
"I am honored to join this pioneering organization which plays an important role in the impact CRISPR has on life science research and clinical development," said Christianson. "Paul is a visionary who has built a foundation upon which Synthego will become the best partner for clients in terms of co-development and regulatory compliance for the advancement of therapies and, ultimately, human health."
Christianson's appointment, along with the spinout of EditCo Bio, previously operating as Synthego's Eclipse platform, reinforces Synthego's commitment to provide CRISPR therapeutic developers with best-in-class guide RNAs. With its state-of-the-art GMP facility and extensive experience of producing leading products, Synthego is uniquely positioned to address escalating clinical requirements and changing regulatory frameworks. Bolstered by the FDA approval of the first CRISPR-based therapy, Synthego is more dedicated than ever to accelerating life-saving technologies for improved human health in its next chapter.
For more information, click here.
About Synthego:Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. Based on a foundation of engineering and chemistry, Synthego leverages automation and machine learning to synthesize high-quality CRISPR reagents for science at scale. Synthego's mission is to enable agile life science research and development from discovery through clinical trials by providing scientists with comprehensive CRISPR solutions for each phase coupled with full technical and regulatory support from industry-leading experts. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale.
SOURCE Synthego
Read more:
Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics - PR Newswire
History Timeline – The Cryonics Institute
1976 ROBERT ETTINGER FOUNDS THE CRYONICS INSTITUTE
Then in 1976 a separate organization was formed: the Cryonics Institute, to offer cryostasis services: careful preparation, cooling, and long term patient care in liquid nitrogen.
Our goal was maximum reliability and affordability. And we achieved it. The Cryonics Institute offers clear-cut advantages over all other providers. Such as:
Our prices are lower than any other organization in fact, the most affordable prices anywhere in the world. Our minimum whole-body suspension fee is $28,000. (For members at a distance, transportation costs and local help will be additional.) Our $28,000 fee is a one-time only payment, with no subsequent charges. Its easily funded by insurance or other means, and funds the best care available for our member patients. (For last-minute cases, where the patient was not signed up beforehand, we ordinarily charge $35,000 rather than $28,000, if arrangements can be worked out at all.)
Does that lower fee mean lower quality patient care or services? No. The major part of other organizations fees are earmarked for investment provisions totally unrelated to patient care and preparation. Methods and research differ, but overall we believe our procedures and policies give a better chance for patient survival than any other organizations and this web site will show you the detailed reasons why.
See for yourself. Read our FAQ and see The CI Advantage that compares the different cryonics organizations and why we think CI gives you and those you love the best possible chance for future survival. Remember: most CI members can afford the higher prices of other organizations for themselves and their families and often do give more, in bequests and donations. But weve chosen CI because we know its our best bet. And yours.
We have a unique, proven track record of financial security and stability. Price stability too. CI is the only organization with no debt, no stockholders, and no landlords. We own our patient care facilities outright, and all our officers and directors donate their services voluntarily. Were one of the oldest cryonics organizations in existence and the only such organization that has never raised its prices, even in high-inflation times like the late 70s and early 80s. Adjusting for inflation, our prices have actually steadily declined, and we expect this to continue.
Financially, we are the soundest cryonics organization in existence.
We have a uniquely flexible and rapid system of emergency patient care based on universally available networks of mortuary assistance (and often medical assistance). This means that in the critical early stages, we can bring qualified professionals to you faster than any other system to you, and to travelers, vacationers, and members throughout most of the world. In particular, London-based F.A. Albin & Sons funeral directors are trained, practiced, equipped, and prepared to fly a team anywhere in Europe on short notice to help European CI members or tourists and business travelers.
And finally, we provide a comprehensive source of information here on CIs website. The site youre reading will lead you to everything you need to know about the subject of cryonics, and more. It offers you free information, free books, the latest news, hundreds of links to thousands of sources covering health, science, cutting-edge medicine, nanotechnology, financial help and resources, and supportive people and organizations. And if thats not enough? We personally will answer any question you might have about cryonics or the Cryonics Institute directly by email, or direct you to someone who can. In the world of cryonics, this is the source to visit, and the place to be.